Filing Analysis
Atea Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the three months ended September 30, 2024. The filing serves as a formal notice that a press release containing these results has been issued.
📋 Key Facts
- Report date: November 7, 2024
- Reporting period: Three months ended September 30, 2024
- The filing includes Exhibit 99.1 (Press Release) regarding financial results and other matters.
- Signed by Andrea Corcoran, CFO and Executive Vice President.
Atea Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the three months ended June 30, 2024. The filing serves as a formal announcement of the release of quarterly earnings data.
📋 Key Facts
- Report date: August 7, 2024
- Reporting period: Three months ended June 30, 2024
- The company issued a press release (Exhibit 99.1) containing financial results and other matters.
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18.
Atea Pharmaceuticals, Inc. held its 2024 Annual Meeting of Stockholders on June 21, 2024. The meeting resulted in the election of two directors and the ratification of the company's independent auditor.
📋 Key Facts
- Annual Meeting held on June 21, 2024.
- Quorum reached with 74,365,479 shares present (approx. 88.29% of outstanding common stock).
- Franklin Berger and Jean-Pierre Sommadossi, Ph.D. were elected to the Board of Directors.
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Shareholders approved executive compensation on an advisory (non-binding) basis.
Atea Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024. The filing serves as a formal announcement of the earnings press release issued on May 14, 2024.
📋 Key Facts
- Reporting period: Three months ended March 31, 2024.
- Filing date: May 14, 2024.
- The filing includes a press release as Exhibit 99.1 regarding results of operations and financial condition.
Atea Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the three months and full year ended December 31, 2023. The filing serves as a formal vehicle to furnish the company's earnings press release.
📋 Key Facts
- Report date: February 28, 2024
- Reporting period: Three months and full year ended December 31, 2023
- The filing includes a press release as Exhibit 99.1 regarding financial results.